Immutep


Contact Us

Immutep S.A. au capital de 247 136 euros- 439 518 663 RCS Evry Siège social : Parc Club Orsay, 2, rue Jean Rostand, 91893 ORSAY



Filling this form is the simpliest way to contact us by email.


If you wish to visit us, please click here for full maps and details.

First Name :

Last Name :

Company (blank if none) :

Title (blank if none) :

Address :

Town :

Zip Code :

Country :

Telephone :

Fax :

E-mail address :

<~ only this field is really required

 

Type in your comments or questions. An Immutep staff member will get back to you shortly.

© 2002 Immutep, S.A.
Press Release
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
image Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
image Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - Interview Frederic Triebel with PharmaTelevision

01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...